Turkish Journal of Medical Sciences




In the present study involving patients with bone metastases arising from prostate cancer, we measured urinary deoxypyridinoline (DPD) as a marker of collagen breakdown activity, serum total and bone-specific alkaline phosphatase activities and serum prostate specific antigen (PSA). This study included 20 patients with benign prostate hyperplasia (BPH) and 23 patients with carcinoma, 11 of had with bone metastases. DPD excretion in urine was significantly greater in prostate cancer patients with bone metastasis than in those with localised prostate cancer or BPH (p0.05). The serum markers of bone formation [total alkaline phosphatase (T-ALP) and bone ALP (B-ALP)] displayed higher mean concentrations in the group with positive bone metastases than in the group with local disease (p

First Page


Last Page